Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy of fluvoxamine in the treatment of major depression with comorbidanxiety disorders
Autore:
Sonawalla, SB; Spillmann, MK; Kolsky, AR; Alpert, JE; Nierenberg, AA; Rosenbaum, JF; Fava, M;
Indirizzi:
Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, Boston,MA 02114 USA Massachusetts Gen Hosp Boston MA USA 02114 s Program, Boston,MA 02114 USA Harvard Univ, Sch Med, Boston, MA USA Harvard Univ Boston MA USAHarvard Univ, Sch Med, Boston, MA USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHIATRY
fascicolo: 9, volume: 60, anno: 1999,
pagine: 580 - 583
SICI:
0160-6689(199909)60:9<580:EOFITT>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBSESSIVE-COMPULSIVE DISORDER; DOUBLE-BLIND; CLINICAL PHARMACOKINETICS; IMIPRAMINE; PLACEBO; CLOMIPRAMINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Sonawalla, SB Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, WACC 812,15 Parkman St, Boston, MA 02114 USA Massachusetts Gen Hosp WACC 812,15 Parkman St Boston MA USA 02114
Citazione:
S.B. Sonawalla et al., "Efficacy of fluvoxamine in the treatment of major depression with comorbidanxiety disorders", J CLIN PSY, 60(9), 1999, pp. 580-583

Abstract

Background: Major depression with comorbid anxiety disorder is associated with poor antidepressant outcome compared with major depression without comorbid anxiety disorder. The purpose of our study was to assess changes in depressive symptoms and anxiety levels in outpatients with major depression with comorbid anxiety disorder following 12 weeks of open treatment with fluvoxamine. Method: We enrolled 30 outpatients (mean +/- SD age = 39.4 +/- 11.3 years;16 women and 14 men) with DSM-IV major depressive disorder accompanied by one or more current comorbid DSM-IV anxiety disorders in our study. Patients were treated openly with fluvoxamine initiated at 50 mg/day, with an upward titration to a maximum of 200 mg/day (mean +/- SD dose = 143 +/- 45 mg/day). Efficacy assessments included the 17-item Hamilton Rating Scale for Depression (HAM-D-17) and Clinical Global Impressions-Severity of Illness (CGI-S) and Improvement (CGI-I) scales for both depression and anxiety. Intent-to-treat analysis was used to assess outcome. Results: The mean +/- SD number of comorbid anxiety disorders per patient was 2.1 +/- 1.1. Following fluvoxamine treatment, the mean +/- SD HAM-D-17 score dropped from 20.2 +/- 3.3 to 11.0 +/- 7.0 (p <.0001). The mean +/- SDdepression CGI-S score dropped from 4.0 +/- 0.6 to 2.4 +/- 1.1 (p <.0001),and the mean si: SD anxiety CGI-S score decreased from 4.1 +/- 0.8 to 2.5 /- 1.2 (p <.0001). Eighteen (60%) of the 30 patients had CGI-I scores lessthan or equal to 2 for both anxiety and depression at endpoint, with 53% showing a greater than or equal to 50% reduction in HAM-D-17 scores at endpoint. Conclusion: Although preliminary, our findings suggest that fluvoxamine iseffective in treating outpatients with major depression with comorbid anxiety disorder, having a significant effect on both depression and anxiety symptoms. Further double-blind, placebo-controlled trials are needed, in a larger sample, to confirm our findings.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/09/20 alle ore 20:09:15